Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Who We Are
    • IP Portfolio
    • Management Team
    • Board of Directors
    • Careers
  • Technology
  • Pipeline
    • Probuphine
    • Ropinirole Implant
    • T3 Implant
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Publications
    • Posters
    • Media Resources
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Company Information
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Titan FCOI Policy
    • Financial Info
    • Financials
    • Financial Results
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact
  • Search

Press Releases

  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Navigate Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Press Releases

  • All News
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Titan Pharmaceuticals Licenses Exclusive Probuphine(R) Commercialization Rights in U.S. and Canada to Braeburn Pharmaceuticals

December 17, 2012

Titan Pharmaceuticals Announces Third Quarter 2012 Financial Results

November 12, 2012

Titan Pharmaceuticals Announces $4.25 Million Stock Purchase and Option Agreement

September 14, 2012

Titan Pharmaceuticals Announces Second Quarter 2012 Financial Results

August 10, 2012

Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2012 Financial Results

August 8, 2012

Titan Completes Preclinical Study of a Continuous, Dopamine Agonist Treatment for Parkinson's Disease

July 9, 2012

Titan Pharmaceuticals Announces First Quarter 2012 Financial Results

May 11, 2012

Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2012 Financial Results

May 9, 2012

Titan Pharmaceuticals Announces Phase 3 Probuphine(R) Data Presentation at the American Society of Addiction Medicine (ASAM) 43rd Medical-Scientific Conference

April 20, 2012

Titan Pharmaceuticals to Raise $5.5 Million in Registered Direct Offering

April 10, 2012

RSS
  • 1
  • 2
  • Next »
© 2021 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap